ArticleDrugs in R&D2023

Pharmacovigilance Study of Infigratinib: A Safety Analysis of the FDA Adverse Event Reporting System.

Dehua Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.